Application of photodynamic therapy with chlorin Е6-polyvinylpyrrolidone complex for chronic central serous chorioretinopathy: pilot study
chorioretinopathy (CSCR) is a chorioretinal disease characterized by the
formation of serous detachment of neuroepithelium, localized most often in the macula
and associated with increased perfusion, and increased thickness of the
vascular membrane leading to decompensation of retinal pigment epithelium
(RPE). When chronic CSCR, there is a high risk of complications such as retinal
RPE atrophy and
subretinal neovascular membrane formation.
Photodynamic therapy (PDT) with
verteporfin is widely used when chronic CSCR. This method of treatment is
successfully used when CSCR with large areas of decompensation of RPE. This
effect is due to short-term choriocapillary hypoperfusion and chorioidal
remodeling, which lead to a decrease in chorioidal overload and vascular layer
insight. However, nowadays verteporfin is not registered in Ukraine.
of the Department of Laser Microsurgery of Eye Diseases of SI "The Filatov
Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine," made
photodynamic therapy (chlorin E6-polyvinylpyrrolidone complex with a dosage of 3 mg/m2 per body surface area). After that, complete resorption of subretinal fluid is noted .
Photodynamic therapy (chlorin E6-polyvinylpyrrolidone
complex) is an effective and safe method of treating patients with chronic
central serous chorioretinopathy.